Abstract
Objective To investigate the clinical efficacy and safety of Xiao'er Chiqiaoqingre granule in the treatment of acute upper respiratory tract infection. Methods From January 2017 to December 2017, a total of 116 children with upper respiratory tract infection in Taizhou Integrated Traditional Chinese and Western Medicine Hospital were selected and randomly divided into control group and observation group according to different treatment regimens, with 58 cases in each group.The control group was given ribavirin granules, ibuprofen suspension drops for treatment.The observation group was given Xiao'er Chiqiaoqingre granule on the basis of the control group.The two groups were treated for 5 days, then the clinical effect, the improvement of clinical symptoms, the time of cure, the level of serum cytokines and safety were compared between the two groups. Results After treatment, the cure rate of the observation group was 96.6%, which was significantly higher than 81.0% of the control group (P 0.05). The serum levels of IL-6, IL-10 and TNF- in the observation group were (108.45±25.61)μg/L, (34.88±9.07)μg/L, (1.26±0.86)mg/mL, respectively, which were significantly lower than those in the control group[(129.27±28.31)μg/L, (43.27±10.09)μg/L, (2.11±1.03)mg/mL](all P<0.05). There were no other serious adverse reactions in the two groups. Conclusion Xiao'er Chiqiaoqingre granule in the treatment of acute upper respiratory tract infection can significantly improve clinical symptoms, improve clinical curative effect, and has good safety and certain clinical value. Key words: Acute upper respiratory tract infection; Xiao'er chiqiaoqingre granule; Ribavirin; Ibuprofen; Adverse reactions
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.